莱布里基祖马布用于中度至重度的无皮炎
Leah Johnston1, Susan Poelman2,3, Andrei Metelitsa2,3
1Department of Dermatology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Skin therapy letter
|July 24, 2025
概括
勒布里奇祖马布有效治疗成人和青少年中度至重度的亚托皮炎 (AD). 本综述总结了临床试验数据,对阿尔茨海默病患者的疗效和安全性.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 亚托皮炎 (AD) 是一种普遍的慢性炎症性皮肤疾病,影响北美10-15%的人.
- 目前对中度至重度AD的治疗方法对许多患者来说存在持续的挑战.
- 互乐金-13 (IL-13) 是一种关键的细胞因子,涉及AD的发病.
研究的目的:
- 审查临床试验数据关于lebrikizumab在治疗中度至重度亚托皮炎的疗效和安全性.
- 为提供lebrikizumab在AD成年患者治疗特征的概述.
主要方法:
- 对有关lebrikizumab的临床试验数据的系统审查.
- 从涉及中度至重度AD的成年患者的研究中对疗效和安全终点的分析.
主要成果:
- 勒布里奇祖马布在改善中度至重度AD的成年患者的临床结果方面表现出显著的有效性.
- 安全数据表明,在研究的人群中,lebrikizumab具有可管理的特征.
结论:
- 勒布里奇祖马布代表了对中度至重度亚托皮性皮炎的有前途的新系统性治疗选择.
- 加拿大和美国的监管批准强调了lebrikizumab在临床实践中的潜力.
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
482
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
482
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
451
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
451
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
235
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
235
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Antiepileptic Drugs: Potassium Channel Activators
278
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
278
Inflammatory Bowel Disease IV: Pharmacological Management
193
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
193


